Key opinion leaders address the availability of brexucabtagene autoleucel (brexu-cel) at their institutions and outline procedures for ensuring risk evaluation and mitigation strategy compliance and comprehensive training across multidisciplinary teams.
For those who have brexu-cel on-formulary or available at your institution, what processes did you and your team take to ensure REMS compliance and training among multidisciplinary team members?
Typically, is a physician, pharmacist, nurse, quality coordinator or another member of the team the REMS Authorized Representative?
At your institution, are patients receiving CAR-T cell Therapy in the outpatient or inpatient setting?
For those infusing CAR-T cell Therapy in the outpatient setting, how are patients being monitored?